Clinical trials: Obesity & Overweight
Obesity, Overweight
A Research Study of How NNC0174-0833 Behaves in Japanese and Caucasian Volunteers Who Are Normal Weight, Overweight or With Obesity
The aim of this study is to look at how the study medicine behaves in the participant's body and how it is removed from the participant's body.
- Trial name
- NCT03787225
- Testing
- NNC0174-0833
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Novo Nordisk A/S
Obesity
SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight
This study is open to women up to 65 years of age who are living with overweight or obesity and are going through or have finished menopause.
- Trial name
- NCT07850050
- Testing
- Survodutide
- Where
- 16 sites in United States, United Kingdom
- Volunteers
- 600 people
- Sponsor
- Boehringer Ingelheim
Obesity and Overweight
A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese
The study is looking at possible new medicines for weight control in people with high body weight. The study looks at how the new medicines work in the body. The study consists of two parts.
- Trial name
- NCT03707990
- Testing
- NNC0165-1875, Semaglutide
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Carotid Artery Plaque, Arteriosclerosis
Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant
Objectives: Primary: To evaluate the effect of rimonabant 20-mg once daily in comparison with placebo, on the quantitative progression of atherosclerosis as assessed by carotid artery intima-media thickness (CIMT) Secondary: To…
- Conditions
- Carotid Artery Plaque, Arteriosclerosis, Obesity, Metabolic Syndrome X
- Trial name
- AUDITOR (NCT00228176)
- Testing
- Rimonabant
- Where
- 6 sites in United States, Canada and 4 more
- Volunteers
- 661 people
- Sponsor
- Sanofi
Obesity, Diabetes
Gelesis Glycemic Index Study
A study to determine glucose and insulin responses to 50g and 100 g of carbohydrate with and without Gelesis200.
- Conditions
- Obesity, Diabetes, PreDiabetes
- Trial name
- GLIDE (NCT03124134)
- Testing
- Gelesis200
- Where
- Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Gelesis, Inc.
Overweight and Obesity
ALY688-SR in Generally Healthy Overweight or Obese Adults
First in human study of ALY688-SR administered as a subcutaneous injection
- Trial name
- NCT04855565
- Testing
- ALY688-SR
- Where
- Australia
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Allysta Pharmaceutical
Gastrointestinal Dysfunction
A Study to Assess the Gut Health Effects of Heat-killed Post-biotics in Overweight and Obese Adults
The present study is a randomized, double-blind (Double dummy), placebo-controlled, parallel-group study to assess the gut health effects of heat-killed post biotics in overweight and obese individuals
- Trial name
- NCT05820737
- Testing
- EF2001, beLP1
- Where
- 9 sites in India
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
Obesity
Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity
This study looks at how well semaglutide helps people lose weight. This study will look at the change in the participants' body weight from the start to the end of the study.
- Trial name
- NCT04998136
- Testing
- Semaglutide 2.4 mg
- Where
- 16 sites in South Korea, Thailand
- Volunteers
- 150 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus (T2DM), Food Effect
Food Effect, Efficacy and Safety of MKP10241 in Healthy and Obese Adult Participants, With and Without Diabetes
The goal of this intervention study is to evaluate the safety, tolerability and pharmacokinetics (PK) and pharmacodynamics (PD) of multiple doses of MKP10241 in obese participants with and without T2DM in 3 parts.
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Food Effect, Safety and Tolerability, Obesity
- Trial name
- NCT07098663
- Testing
- MKP10241
- Where
- Australia
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Mankind Pharma Limited
Obesity (Disorder), Overweight , Obesity
I-OPERA: A European Study Testing a New Way to Do Health Research.
The goal of this observational pilot study is to evaluate whether a participant-mediated, direct-to-participant research approach is a feasible and effective way to collect health data from adults living with obesity in England…
- Trial name
- I-OPERA (NCT07759544)
- Volunteers
- 105 people
- Sponsor
- IQVIA RDS Spain, SL
Metabolism and Nutrition Disorder, Obesity
Investigation of Single Ascending Doses of NNC9204-1706 in Male Subjects Being Overweight or With Obesity
This trial is conducted in the United States of America (USA). The aim of this trial is to assess the safety and tolerability of single doses of NNC9204-1706 administered subcutaneously in male subjects being overweight or with…
- Trial name
- NCT03095807
- Testing
- NNC9204-1706 A
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Novo Nordisk A/S
Healthy, Non-diabetic Overweight or Obese
A Study of BGM0504 Tablets in Healthy and Non-diabetic Overweight or Obese Chinese Subjects
A Randomized, Double-Blind, Placebo-Controlled, Single/Multiple-dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BGM0504 Tablets Orally Administered in Healthy and Non-diabetic Overweight or Obese…
- Trial name
- NCT07239973
- Testing
- BGM0504 tablets
- Where
- China
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Obesity
BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus
The purpose of this study is to assess the weight loss effect of lorcaserin during and at the end of 1 year of treatment in overweight and obese patients with Type II diabetes mellitus treated with metformin, sulfonylurea (SFU)…
- Trial name
- NCT00603291
- Testing
- Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID)
- Where
- United States
- Volunteers
- 604 people
- Sponsor
- Eisai Inc.
Hypertension With Overweight or Obesity
Phase III Study of HRS-7535 for Hypertension With Overweight or Obesity
The main objective of this study is to demonstrate the superior efficacy of HRS-7535 in controlling blood pressure compared to placebo in subjects with hypertension and overweight or obesity;
- Trial name
- NCT07528027
- Testing
- HRS-7535
- Where
- 2 sites in China
- Volunteers
- 648 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Type 2 Diabetes, Obesity
A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity
This is a multicenter, randomized, Open-label Phase 3 clinical study comparing the efficacy and safety of IBI362 6 mg OW versus Semalgutide 1 mg OW in obese(BMI≥28kg/m2) early T2D subjects.
- Trial name
- NCT06184568
- Testing
- IBI362, Semaglutide
- Where
- China
- Volunteers
- 349 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Overweight or Obese Participants Without Diabetes
A Study to Evaluate Efficacy and Safety of BGM0504 Tablets in Overweight or Obese Participants Without Diabetes
To evaluate the efficacy of BGM0504 tablets compared with placebo in reducing body weight in overweight or obese participants without diabetes after 20 weeks of treatment.
- Trial name
- NCT07658560
- Testing
- BGM0504 tablets
- Where
- China
- Volunteers
- 200 people
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Obesity
Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)
The fixed-dose combination of naltrexone 8mg and bupropion 90mg extended-release oral tablet is marketed under the trade name CONTRAVE® in the U.S.
- Trial name
- HOA (NCT06090461)
- Where
- United States
- Volunteers
- 31,889 people
- Sponsor
- Currax Pharmaceuticals
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
- Trial name
- MARITIME-2 (NCT06858878)
- Testing
- Maridebart cafraglutide
- Where
- 187 sites in United States, Argentina and 11 more
- Volunteers
- 1,105 people
- Sponsor
- Amgen
Obesity
A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity
The main purpose of this study is to evaluate the safety and tolerability of tirzepatide (LY3298176) in pediatric participants with obesity.
- Trial name
- NCT05696847
- Testing
- Tirzepatide
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Eli Lilly and Company
Obesity
SUCCESS Tracking Study
The overall purpose of this research is to evaluate the long-term outcomes associated with participation in Medifast Direct and Take Shape For Life weight-loss programs in comparison with non-Medifast weight-loss programs.
- Trial name
- NCT01021917
- Where
- United States
- Volunteers
- 332 people
- Sponsor
- Medifast, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.